bioAffinity Technologies (BIAF) Stock Price, News & Analysis

Company Overview

bioAffinity Technologies, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive, immunoassay-based tests for the early detection and monitoring of cancer. Founded in 2009 and incorporated in the Cayman Islands, the company maintains its principal executive offices in Miami, Florida. bioAffinity’s platform leverages proprietary monoclonal antibodies to target epigenetic biomarkers, enabling sensitive and specific assays suitable for routine laboratory use.

The company’s lead product candidate, the UMA-1™ Bladder Cancer Test, is a urine-based assay designed to detect bladder cancer at its earliest stages. By identifying aberrant methylation patterns in urinary cells, UMA-1 aims to offer clinicians a convenient alternative to invasive cystoscopy procedures and improve patient compliance with surveillance protocols. bioAffinity is also advancing a pipeline of additional assays for the detection of lung and colorectal cancers, employing the same immunoassay technology to address diagnostic gaps across multiple tumor types.

bioAffinity operates through partnerships with CLIA-certified laboratories in the United States and is seeking regulatory clearances to expand its market reach. The company’s strategy includes collaboration with academic medical centers and diagnostic laboratories to validate its assays in diverse patient populations. In parallel, bioAffinity is exploring distribution agreements for international markets, with a focus on regions where non-invasive testing could alleviate healthcare system burdens and reduce overall diagnostic costs.

Leadership at bioAffinity comprises seasoned executives and board members with extensive experience in molecular diagnostics, oncology, and commercial development. Michael McMahon serves as President and Chief Executive Officer, guiding corporate strategy and clinical development programs. Under this leadership, bioAffinity continues to build its intellectual property portfolio, advance regulatory filings, and establish strategic collaborations aimed at transforming cancer diagnostics through innovative, patient-friendly testing solutions.

Key Stats

• Today's Range: $0.28 to $0.32
• 50-Day Range: $0.20 to $0.45
• 52-Week Range: $0.16 to $2.99
• Volume: 538,126 shs
• Average Volume: 4.16 million shs
• Market Capitalization: $8.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

bioAffinity Technologies Stock Analysis - MarketRank™

bioAffinity Technologies scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

bioAffinity Technologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

bioAffinity Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of bioAffinity Technologies is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of bioAffinity Technologies is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

bioAffinity Technologies has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.31% of the float of bioAffinity Technologies has been sold short.

Short Interest Ratio / Days to Cover

bioAffinity Technologies has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in bioAffinity Technologies has recently increased by 470.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

bioAffinity Technologies does not currently pay a dividend.

Dividend Growth

bioAffinity Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.31% of the float of bioAffinity Technologies has been sold short.

Short Interest Ratio / Days to Cover

bioAffinity Technologies has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in bioAffinity Technologies has recently increased by 470.95%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.19

News Sentiment

bioAffinity Technologies has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for bioAffinity Technologies this week, compared to 0 articles on an average week.

MarketBeat Follows

2 people have added bioAffinity Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.93% of the stock of bioAffinity Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.64% of the stock of bioAffinity Technologies is held by institutions.

BIAF Stock Analysis - Frequently Asked Questions

How have BIAF shares performed this year?

bioAffinity Technologies' stock was trading at $0.91 at the beginning of the year. Since then, BIAF shares have decreased by 66.3% and is now trading at $0.3068.

How were bioAffinity Technologies' earnings last quarter?

bioAffinity Technologies, Inc. (NASDAQ:BIAF) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.16) EPS for the quarter, meeting analysts' consensus estimates of ($0.16). The company earned $1.85 million during the quarter, compared to analyst estimates of $2.11 million. bioAffinity Technologies had a negative trailing twelve-month return on equity of 367.64% and a negative net margin of 110.53%.

When did bioAffinity Technologies IPO?

bioAffinity Technologies (BIAF) raised $8 million in an IPO on Thursday, September 1st 2022. The company issued 1,300,000 shares at $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager.

How do I buy shares of bioAffinity Technologies?

Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of bioAffinity Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that bioAffinity Technologies investors own include Lowe's Companies (LOW), Meta Platforms (META), Costco Wholesale (COST), Intel (INTC), AIM ImmunoTech (AIM), Alnylam Pharmaceuticals (ALNY) and Ambrx Biopharma (AMAM).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:BIAF
• CIK: 1712762
• Web: www.bioaffinitytech.com
• Phone: 210-698-5334
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for bioAffinity Technologies: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +1,855.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.04 million
• Net Margins: -110.53%
• Pretax Margin: -110.35%
• Return on Equity: -367.64%
• Return on Assets: -154.15%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 0.55
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $8.81 million
• Price / Sales: 0.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 1.80

Miscellaneous

• Outstanding Shares: 28,460,000
• Free Float: 23,642,000
• Market Cap: $8.73 million
• Optionable: Not Optionable
• Beta: 2.52